{
  "docId": "019de075-dd1e-7468-9323-d12fde1b7732",
  "docSlug": "a9cc0c508d45d8985f57408ace49b969",
  "documentTitle": "RayzeBio | IPO Presentation Deck | 41 slides",
  "authorId": "rayzebio",
  "authorName": "RayzeBio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2023-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 5,
  "pageCount": 41,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 1,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/5",
  "deckHref": "/decks/019de075-dd1e-7468-9323-d12fde1b7732",
  "deckJsonHref": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json",
  "deckAnchorHref": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.28,
        "x": 0.03,
        "y": 0.58
      },
      "kind": "callout",
      "text": "Blockbuster Potential with GPC3 or Other programs",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5d70eaf5-1f3a-42ef-8834-ba2873844af4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.38,
        "w": 0.28,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "callout",
      "text": "SSTR2 – Potential Market leading sustainable franchise",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ab618ba-97ec-45ae-91cf-06b83f306248",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.94,
        "x": 0.03,
        "y": 0.78
      },
      "kind": "callout",
      "text": "World-class Capabilities and Infrastructure",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c94333b3-004e-47c0-a67a-e1846af07c6c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.38,
        "w": 0.66,
        "x": 0.31,
        "y": 0.14
      },
      "kind": "list",
      "text": "RYZ101 in late line GEP-NETs presents significant market opportunity; No approved drugs post 177Lu setting; SSTR2 expression in ES-SCLC; RYZ101 drug protection; Life cycle management with novel SSTR2 binder",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a46db965-c677-4b63-87d0-6363e172cba6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.66,
        "x": 0.31,
        "y": 0.81
      },
      "kind": "list",
      "text": "Industry leading knowledge on 225Ac; Supply agreements for 225Ac; Commercial scale RayzeBio centralized GMP facility",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b9ca17fa-3aa3-4671-bfc7-604b0bae16a3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.66,
        "x": 0.31,
        "y": 0.58
      },
      "kind": "list",
      "text": "RYZ801 targeting GPC3 (liver cancer); 41,000 new liver cancer expected in the U.S. in 2023; Additional discovery programs",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e4575b50-f61b-4465-a6e5-86bb4f97b161",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "Product Focused Approach",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fb2f4be1-b1dc-4e83-9403-d9a94235eb46",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "c62bbe63-e8da-4211-9c57-92da1f327155",
      "evidence": "list/bullet: RYZ101 in late line GEP-NETs presents significant market opportunity; No approved drugs post 177Lu setting; SSTR2 expression in ES-SCLC; RYZ101 drug protection; Life cycle management with novel SSTR2 binder",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}